▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 29, 2024

Bio

Daewon Pharmaceutical signs deal with Richter-Helm BioTec to launch Forsteo biosimilar

  • PUBLISHED :February 23, 2017 - 17:16
  • UPDATED :February 23, 2017 - 17:16
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] South Korea’s Daewon Pharmaceutical is seeking to enter the local biosimilar market with a plan to launch a copycat version of Eli Lilly’s blockbuster drug Forsteo developed by a German biotechnology firm, the company said on Feb. 23.

Daewon Pharmaceutical entered a license agreement with Richter-Helm BioTec to sell Terrosa, the treatment for osteoporosis, in South Korea. 




“The agreement is a meaningful step for Daewon Pharmaceutical as Terrosa will be our first biosimilar drug to be released through domestic approval,” the company said.

Terms and conditions of the deal have not been disclosed.

The launch is expected after the patent for the original product Forsteo, which generated US$1.3 billion of sales in 2015, expires in September 2019.

In November 2016, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for Terrosa.

According to the EMA, studies have shown Terrosa to have comparable quality, safety and efficacy to the original drug Forsteo.

Terrosa will be available as a solution for injection. The active substance of Terrosa is teriparatide, the active aminoterminal fragment of human parathyroid hormone.

Richter-Helm BioTec is a joint venture between Hungary-based Gedeon Richter and Germany‘s Helm.

On the news, Daewon Pharmaceutical shares climbed 2.45 percent to trade at 20,900 won (US$18.36) as of 3 p.m.

By Park Han-na (hnpark@heraldcorp.com)

EDITOR'S PICKS